Barry S Rodgers-Gray (B S Rodgers-Gray, Barry Rodgers-Gray, B Rodgers-Gray)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 5

Top Topics

Respiratory Syncytial Virus

Preterm Infants

Top Venues

Multiple sclerosis journal - experimental, translational and clinical

Journal of medical economics

Current medical research and opinion

This page only lists publications with an associated author ORCID identifier.

Publications

Barry S Rodgers-Gray, John R Fullarton, Xavier Carbonell-Estrany, Ian P Keary, Jean-Eric Tarride, Bosco A Paes
Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants. Journal of medical economics (2023)
Ian P Keary, Roberto Ravasio, John R Fullarton, Paolo Manzoni, Marcello Lanari, Bosco A Paes, Xavier Carbonell-Estrany, Eugenio Baraldi, Jean-Éric Tarride, Barry S Rodgers-Gray
A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age. PloS one 18 (8) (2023)
Bosco A Paes, John R Fullarton, Barry S Rodgers-Gray, Xavier Carbonell-Estrany
Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants. Current medical research and opinion 37 (7) (2021)
M Lanari, E J Anderson, M Sheridan-Pereira, X Carbonell-Estrany, B Paes, Barry S Rodgers-Gray, J R Fullarton, E Grubb, M Blanken
Burden of respiratory syncytial virus hospitalisation among infants born at 32-35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies. Epidemiology and infection 148 (2020)
G Giovannoni, P A Brex, D Dhiraj, J Fullarton, M Freddi, Barry S Rodgers-Gray, Klaus Schmierer
Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme. Multiple sclerosis journal - experimental, translational and clinical 5 (4) (2019)